What We're Reading: Page 43
Industry reads hand-picked by our editors
Oct 03, 2024
-
The Financial Times
China’s WuXi explores sale of pharma units as US restrictions loom
-
Bloomberg
US’s $100 Billion HIV Program Commits to African Manufacturing
-
Fierce Biotech
Big pharma, biotech relations ‘won’t necessarily be symbiotic’ in future AI landscape: S&P
-
Nature
Can flashing lights stall Alzheimer’s? What the science shows
Oct 02, 2024
Oct 01, 2024
-
The Wall Street Journal
CVS Board Conducts Strategic Review of Company
-
Reuters
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
-
FirstWord Pharma
Shattuck abandons lead cancer asset after survival data disappoint, pivots to IBD
Sep 30, 2024
Sep 27, 2024
-
Science
Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?
-
The New York Times
New R.S.V. Vaccines Had Limited Takers Last Year. Will This Year be Better?
-
Financial Times
Inside the ‘killer cell’ factory
-
The Wall Street Journal
Why Drug Distributors Are Buying Cancer Specialists
Sep 26, 2024
-
Endpoints News
J&J folds cardiovascular and metabolic drug unit
-
Financial Times
How tackling TB could help win the war on superbugs
-
Nature News
Why do obesity drugs seem to treat so many other ailments?
Previous
